Neurologie Berlin, Clinical Practice and Study Center

The Neurologie Berlin site is conducting research on chronic inflammatory demyelinating polyneuropathy, an immune‑mediated nerve condition, with the goal of evaluating new therapeutic options.

• Assessment of riliprubart efficacy using the INCAT disability scale
• Investigation of long‑term benefits for patients who have exhausted standard treatments
• Exploration of safety and tolerability in a population with limited existing options

These studies aim to expand treatment choices for individuals affected by immune‑driven neuropathies and improve overall functional outcomes.

Research at Neurologie Berlin also addresses Parkinson's disease and the associated symptom of apathy, seeking to find effective interventions for motivation deficits.

• Evaluation of safety and tolerability of IRL757 with repeated daily dosing
• Measurement of changes in apathy severity across multiple dose levels
• Identification of optimal dosing regimens to support patient quality of life

The purpose of these trials is to fill unmet needs in non‑motor symptom management for Parkinson’s patients and to enhance therapeutic strategies.